Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10%

MT Newswires Live08-11

Gan & Lee Pharmaceuticals (SHA:603087) granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.

The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.

Menarini will pay a non-refundable, initial payment of 62 million euros to Gan & Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.

Shares surged 10% during afternoon trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658967961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 14:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658967961","market":"fut","top_or_hot":-1,"title":"Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10%","media":"MT Newswires Live","content":"<html><body><p> Gan &amp; Lee Pharmaceuticals (SHA:603087) granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.</p><p>The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.</p><p>Menarini will pay a non-refundable, initial payment of 62 million euros to Gan &amp; Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.</p><p>Shares surged 10% during afternoon trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-11 14:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Gan &amp; Lee Pharmaceuticals (SHA:603087) granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.</p><p>The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.</p><p>Menarini will pay a non-refundable, initial payment of 62 million euros to Gan &amp; Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.</p><p>Shares surged 10% during afternoon trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658967961","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658967961","pubTimestamp":1786430972,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gan & Lee Pharmaceuticals  granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.Menarini will pay a non-refundable, initial payment of 62 million euros to Gan & Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.Shares surged 10% during afternoon trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造"},"translate_title":"Gan&Lee Pharmaceuticals授予Menarini在欧洲开发糖尿病药物的许可权；股价上涨 10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":0.9},"content_text":"Gan & Lee Pharmaceuticals (SHA:603087) granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.Menarini will pay a non-refundable, initial payment of 62 million euros to Gan & Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.Shares surged 10% during afternoon trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658967961","isCrawlerRequest":true}